Researchers at the University Hospital of Bonn and the University of Bonn used a direct conversion technique that skips the embryonic "blank slate" stage, transforming erythroid progenitor cells from 15 donors, aged from newborn to 101, into induced neural stem cells.
They delivered two transcription factors via a virus to trigger the change. By the 12th day, the cells had dropped their blood-like proteins and begun expressing neural proteins. Over the following 50 to 100 days, the cells kept growing biologically younger, resetting most epigenetic age-related traits by around day 50.
"We also know that this epigenetic rejuvenation ensures that the cells actually behave like young cells," said Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University Hospital of Bonn.
The rejuvenated cells displayed less DNA damage and mitochondrial toxicity, and they continued to de-age even when their ability to divide was inhibited, suggesting the reset does not depend on cell proliferation.
The team acknowledged limitations, including potential mathematical biases in de-aging models, the absence of naturally aged neural stem cells for comparison, and possible differences between how cells behave in the lab and in a living body.
Earlier work by the same Bonn group found that similar engineered cells formed connections with existing neurons after being transplanted into the brains of mice, pointing toward future therapeutic applications. Brüstle said the slow, weeks-long reset makes the model particularly useful for studying which factors and active substances accelerate or slow down the rejuvenation process.